drugset / Trial / NCT05706207
A Study of HB0030 Injection in Patients With Advanced Solid Tumors
Phase 1
Unknown
36 enrolled
Huabo Biopharm Co., Ltd.
The First Affiliated Hospital of Bengbu Medical University · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase Ia single-center, open-label, dose escalation study.The objectives of this study are to evaluate the safety, toxicity, tolerability, pharmacokinetics/pharmacodynamics(PK/PD), immunogenicity, biomarkers, and antitumor activity of HB0030 in advanced solid tumor subjects.
Timeline
- Start
- 2021-12-21
- Primary completion
- 2023-09-30
- Completion
- 2023-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB0030 | Monoclonal antibody | 0.03 mg/kg | Intravenous |
| Subject | HB0030 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | HB0030 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | HB0030 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | HB0030 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | HB0030 | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | HB0030 | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | HB0030 | Monoclonal antibody | 40 mg/kg | Intravenous |